Over the years, the R & D team of Sinopharm has been based on independent research and development, grafted with superior technologies, constantly achieved scientific research innovation and technological breakthroughs, and achieved fruitful scientific and technological achievements. As of 2021:

—— Through independent research and development, 36 patents were obtained, including 30 invention patents, 5 utility model patents and 1 design patent.

—— 40 new veterinary drug registration certificates were obtained. In particular, the live porcine reproductive and respiratory syndrome chimeric virus vaccine (PC strain) obtained the new veterinary drug registration certificate is the first and only blue ear chimeric vaccine in the world, leading the industry's leading technology.

—— Nearly 40 scientific and technological achievements at or above the municipal level were obtained. Among them, the research on Key Technologies of high-efficient cytotoxic live swine fever vaccine won the third prize of the China Agricultural Science and Technology Progress Award in November 2011, the establishment and application of the prevention and control technology system of major reproductive disorders of pigs won the second prize of the national science and Technology Progress Award in November 2011, and the innovation and integrated application of major swine disease prevention and control technology in China won the second prize of the national science and Technology Progress Award in December 2016.

—— It has undertaken more than 20 scientific and technological projects of governments at or above the municipal level. Among them, the research and development of genetic engineering vaccine (PC strain) of porcine blue ear disease is listed in the National 863 plan of the 12th Five Year Plan, the industrialization of animal biological products for major animal disease prevention and control is listed in the national torch plan, and the construction project of animal genetic engineering biological products industrialization base is listed in the national biological diagnosis and treatment preparation industry development pilot.

In recent years, the number of independent research and cooperative research projects of the company's R & D center and the number of new products applied for clinical application and registration have attracted the attention of the industry. The company has achieved zero breakthroughs in product independent research and development, national technology awards, national industrialization projects, invention patents, etc. it has accumulated advanced R & D technology and experience in the fields of whole virus (bacteria) vaccines, genetic engineering vaccines, diagnostic reagents, therapeutic agents, etc, It has become one of the few domestic animal vaccine enterprises with the ability to create new products.

At the same time of product research and development, the R & D center has been committed to production technology improvement and process innovation, and has made major breakthroughs:

BIOREACTOR SUSPENSION CULTURE TECHNOLOGY — bioreactor large-scale mammalian cell culture technology is the most advanced vaccine production technology. Its production process is automated, the cell culture density is high, the virus titer is 50-100 times that of the traditional flask culture technology, and the produced vaccine antigen content is high and the quality is stable. The company has established the cascade amplification process flow and quality control system of bioreactor microcarrier suspension culture, and has applied for a number of invention patents.

CELL CULTURE SOLUTION DEVELOPMENT TECHNOLOGY — the independently developed CP formula of special cell nutrient solution for classical swine fever virus, supplemented by special virus proliferation process and unique virus particle purification technology, makes the virus content of cell venom reach 1 million times, 20 times of the national standard, breaking the highest record of domestic and foreign BT cell production of classical swine fever vaccine, and greatly improving the quality of live swine fever vaccine.

CELL BATCH FREEZING TECHNOLOGY  — it can realize batch freezing of 20 passaged cells (30000 ml) in liquid nitrogen at - 196 ℃, breaking the technical bottleneck of cell batch freezing and improving the production efficiency. Antigen concentration and purification technology - the antigen column chromatography purification technology is first applied to the development of animal vaccines in China. Combined with the antigen ultrafiltration and concentration technology, the removal rate of heteroprotein of antigen is up to 95%. The produced animal vaccines have high purity, stable quality and no immune side reactions.

CELL TRANSFER BOTTLE SUSTAINABLE CULTURE TECHNOLOGY — it has broken through the technical problem that ibrs-2 cell line in the industry is difficult to carry out continuous and stable expansion in large-scale production.

For more than ten years, the company has gathered its own outstanding capabilities in product research and development, technological innovation, and transformation of agricultural scientific and technological achievements. The company has been recognized as the implementation unit of major special projects of agricultural scientific and technological industrialization in Wuhan, the first batch of innovative pilot enterprises in Wuhan, the top ten scientific and technological innovation enterprises in Wuhan, the top 50 agricultural scientific and technological innovation enterprises in Hubei Province, the enterprise technology center recognized in Hubei Province Hubei innovative enterprise construction pilot unit, Hubei agricultural science and technology innovation demonstration enterprise, Hubei science and technology small and medium-sized enterprise growth roadmap plan key cultivation enterprise, Hubei agricultural science and Technology Achievements Transformation Fund Project excellent implementation unit, Hubei agricultural industry university research cooperation excellent enterprise, Hubei innovative enterprise, Hubei first batch of Intellectual Property Demonstration construction enterprises, National Torch Plan key high-tech enterprises It is a national high-tech enterprise.

Innovation is the first driving force leading the development of enterprises. The persistent scientific and technological innovation activities, like the powerful "engine", have helped Sinopharm to gallop on the "fast lane" of development, leaping from peak to peak. On the big stage of Sinopharm, scientific and technological innovation will not stop, and it will be brilliant and blooming again!